

Behandling och sociala stödinsatser vid
samsjuklighet mellan beroende och
andra psykiatriska tillstånd/Treatment
and social support measures in case of
comorbidity between addiction and
other psychiatric conditions, report
372
(2025)

Bilaga 3 Studier med oacceptabelt hög eller hög risk för bias/Appendix 3 Studies with critical or high risk of bias

Reference
Ahmadi J, Mansoori A, Mosavat SH, Bazrafshan A. Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: A randomized controlled trial. International Journal of Psychiatry in Medicine. 2024;59(5):521-35. Available from: https://doi.org/10.1177/00912174231225087
Ahmadi J, Sefidfard Jahromi M. Ultrarapid Influence of Buprenorphine on Major Depression in Opioid-Dependent Patients: A Double Blind, Randomized Clinical Trial. Substance use & misuse. 2018;53(2):286-9. Available from: https://doi.org/10.1080/10826084.2017.1400063
Altamura AC, Mauri MC, Girardi T, Panetta B. Alcoholism and depression: a placebo controlled study with viloxazine. International journal of clinical pharmacology research. 1990;10(5):293-8.
Altintoprak AE, Zorlu N, Coskunol H, Akdeniz F, Kitapcioglu G. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. Human psychopharmacology. 2008;23(4):313-9. Available from: https://doi.org/10.1002/hup.935
Back SE, McCauley JL, Korte KJ, Gros DF, Leavitt V, Gray KM, et al. A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders. The Journal of clinical psychiatry. 2016;77(11):e1439-e46. Available from: https://doi.org/10.4088/JCP.15m10239
Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. The British journal of psychiatry : the journal of mental science. 2006;188:439-48. Available from: https://doi.org/10.1192/bjp.188.5.439
Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, et al. Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction (Abingdon, England). 2002;97(10):1329-37. Available from: https://doi.org/10.1046/j.1360-0443.2002.00178.x

Reference
Ball SA. Comparing individual therapies for personality disordered opioid dependent patients. <i>J Pers Disord</i>. 2007;21(3):305-21. Available from: https://doi.org/10.1521/pedi.2007.21.3.305
Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. <i>Archives of General Psychiatry</i>. 2006;63(4):426-32. Available from: https://doi.org/10.1001/archpsyc.63.4.426
Beutler LE, Moleiro C, Malik M, Harwood TM, Romanelli R, Gallagher-Thompson D, et al. A comparison of the Dodo, EST, and ATI factors among comorbid stimulant-dependent, depressed patients. <i>Clinical Psychology and Psychotherapy</i>. 2003;10(2):69-85. Available from: https://doi.org/10.1002/cpp.354
Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS. Generalizability of the results of efficacy trials in first-episode schizophrenia: Comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). <i>Journal of Clinical Psychiatry</i>. 2010;71(1):58-65. Available from: https://doi.org/10.4088/JCP.08m04506yel
Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. <i>Alcoholism, clinical and experimental research</i>. 2005;29(3):395-401. Available from: https://doi.org/10.1097/01.alc.0000156129.98265.57
Brady KT, Sonne SC, Malcolm RJ, Randall CL, Dansky BS, Simpson K, et al. Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. <i>Exp Clin Psychopharmacol</i>. 2002;10(3):276-85. Available from: https://doi.org/10.1037//1064-1297.10.3.276
Brooner RK, Kidorf M, King VL, Stoller K. Preliminary evidence of good treatment response in antisocial drug abusers. <i>Drug and alcohol dependence</i>. 1998;49(3):249-60. Available from: https://doi.org/10.1016/s0376-8716(98)00018-0
Brown ES, Gabrielson B. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. <i>Journal of Affective Disorders</i>. 2012;143(1):257-60. Available from: https://doi.org/10.1016/j.jad.2012.05.006
Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. <i>J Clin Psychopharmacol</i>. 2007;27(5):498-502. Available from: https://doi.org/10.1097/JCP.0b013e31814db4c4
Brown SA, Glasner-Edwards SV, Tate SR, McQuaid JR, Chalekian J, Granholm E. Integrated cognitive behavioral therapy versus twelve-step facilitation therapy for substance-dependent adults with depressive disorders. <i>Journal of psychoactive drugs</i>. 2006;38(4):449-60. Available from: https://doi.org/10.1080/02791072.2006.10400584

Reference
Brunette MF, Dawson R, O'Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, et al. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. <i>Journal of Dual Diagnosis</i>. 2011;7(1):50-63. Available from: https://doi.org/10.1080/15504263.2011.570118
Carpenter KM, Smith JL, Aharonovich E, Nunes EV. Developing therapies for depression in drug dependence: results of a stage 1 therapy study. <i>The American journal of drug and alcohol abuse</i>. 2008;34(5):642-52. Available from: https://doi.org/10.1080/00952990802308171
Ciraulo DA, Barlow DH, Gulliver SB, Farchione T, Morissette SB, Kamholz BW, et al. The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. <i>Behaviour research and therapy</i>. 2013;51(11):729-35. Available from: https://doi.org/10.1016/j.brat.2013.08.003
Ciraulo DA, Knapp C, Rotrosen J, Sarid-Segal O, Ciraulo AM, LoCastro J, et al. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. <i>Addiction (Abingdon, England)</i>. 2005;100:23-31. Available from: https://doi.org/10.1111/j.1360-0443.2005.00984.x
Coffey SF, Stasiewicz PR, Hughes PM, Brimo ML. Trauma-focused imaginal exposure for individuals with comorbid posttraumatic stress disorder and alcohol dependence: revealing mechanisms of alcohol craving in a cue reactivity paradigm. <i>Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors</i>. 2006;20(4):425-35. Available from: https://doi.org/10.1037/0893-164X.20.4.425
Cuomo I, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, et al. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. <i>Neuropsychiatric disease and treatment</i>. 2018;14:1645-56. Available from: https://doi.org/10.2147/NDT.S171002
De Leon G, Sacks S, Staines G, McKendrick K. Modified therapeutic community for homeless mentally ill chemical abusers: Treatment outcomes. <i>American Journal of Drug and Alcohol Abuse</i>. 2000;26(3):461-80. Available from: https://doi.org/10.1081/ada-100100256
DeMarce JM, Lash SJ, Stephens RS, Grambow SC, Burden JL. Promoting continuing care adherence among substance abusers with co-occurring psychiatric disorders following residential treatment. <i>Addictive behaviors</i>. 2008;33(9):1104-12. Available from: https://doi.org/10.1016/j.addbeh.2008.02.008
Drapkin ML, Tate SR, McQuaid JR, Brown SA. Does initial treatment focus influence outcomes for depressed substance abusers? <i>Journal of substance abuse treatment</i>. 2008;35(3):343-50. Available from: https://doi.org/10.1016/j.jsat.2007.12.005

Reference
Fisher MS, Sr., Bentley KJ. Two group therapy models for clients with a dual diagnosis of substance abuse and personality disorder. Psychiatr Serv. 1996;47(11):1244-50. Available from: https://doi.org/10.1176/ps.47.11.1244
Fletcher TD, Cunningham JL, Calsyn RJ, Morse GA, Klinkenberg WD. Evaluation of treatment programs for dual disorder individuals: modeling longitudinal and mediation effects. Administration and Policy in Mental Health. 2008;35(4):319-36. Available from: https://doi.org/10.1007/s10488-008-0170-2
Frisman LK, Mueser KT, Covell NH, Lin H-J, Crocker A, Drake RE, et al. Use of integrated dual disorder treatment via assertive community treatment versus clinical case management for persons with co-occurring disorders and antisocial personality disorder. The Journal of nervous and mental disease. 2009;197(11):822-8. Available from: https://doi.org/10.1097/NMD.0b013e3181beac52
Glasner-Edwards S, Tate SR, McQuaid JR, Cummins K, Granholm E, Brown SA. Mechanisms of action in integrated cognitive-behavioral treatment versus twelve-step facilitation for substance-dependent adults with comorbid major depression. J Stud Alcohol Drugs. 2007;68(5):663-72. Available from: https://doi.org/10.15288/jsad.2007.68.663
Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community mental health journal. 2003;39(3):189-202. Available from: https://doi.org/10.1023/a:1023371705506
Hall JA, Vaughan-Sarrazin M, Reedy AR, Huber DL. Comprehensive case management for substance abuse clients who have mood or anxiety disorders. Mental Health and Substance Use: dual diagnosis. 2008;1(2):143-57. Available from: https://doi.org/10.1080/17523280802019935
Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. American Journal on Addictions. 1995;4(1):33-42. Available from: https://doi.org/10.3109/10550499508997421
Hien DA, Cohen LR, Miele GM, Litt LC, Capstick C. Promising treatments for women with comorbid PTSD and substance use disorders. The American journal of psychiatry. 2004;161(8):1426-32. Available from: https://doi.org/10.1176/appi.ajp.161.8.1426
Jariani M, Saaki M, Nazari H, Birjandi M. The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatria Danubina. 2010;22(4):544-7.
Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. J Nerv Ment Dis. 1995;183(9):566-76. Available from: https://doi.org/10.1097/00005053-199509000-00002

Reference
Kemp DE, Gao K, Ganocy SJ, Elhaj O, Bilali SR, Conroy C, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. <i>The Journal of clinical psychiatry</i> . 2009;70(1):113-21. Available from: https://doi.org/10.4088/jcp.07m04022
Kikkert M, Goudriaan A, de Waal M, Peen J, Dekker J. Effectiveness of Integrated Dual Diagnosis Treatment (IDDT) in severe mental illness outpatients with a co-occurring substance use disorder. <i>Journal of substance abuse treatment</i> . 2018;95:35-42. Available from: https://doi.org/10.1016/j.jsat.2018.09.005
Lôo H, Malka R, Defrance R, Barrucand D, Benard JY, Niox-Rivière H, et al. Tianeptine and amitriptyline. Controlled double-blind trial in depressed alcoholic patients. <i>Neuropsychobiology</i> . 1988;19(2):79-85. Available from: https://doi.org/10.1159/000118439
Machielsen MWJ, Veltman DJ, van den Brink W, de Haan L. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. <i>Schizophrenia research</i> . 2018;194:32-8. Available from: https://doi.org/10.1016/j.schres.2017.03.030
McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. <i>The American journal on addictions</i> . 2010;19(6):481-9. Available from: https://doi.org/10.1111/j.1521-0391.2010.00076.x
Messina N, Farabee D, Rawson R. Treatment responsivity of cocaine-dependent patients with antisocial personality disorder to cognitive-behavioral and contingency management interventions. <i>Journal of consulting and clinical psychology</i> . 2003;71(2):320-9. Available from: https://doi.org/10.1037/0022-006x.71.2.320
Morse GA, Calsyn RJ, Dean Klinkenberg W, Helminiak TW, Wolff N, Drake RE, et al. Treating homeless clients with severe mental illness and substance use disorders: costs and outcomes. <i>Community mental health journal</i> . 2006;42(4):377-404. Available from: https://doi.org/10.1007/s10597-006-9050-y
Na PJ, Ralevski E, Jegede O, Wolfgang A, Petrakis IL. Depression and/or PTSD Comorbidity Affects Response to Antidepressants in Those With Alcohol Use Disorder. <i>Frontiers in psychiatry</i> . 2021;12:768318. Available from: https://doi.org/10.3389/fpsy.2021.768318
Neufeld KJ, Kidorf MS, Kolodner K, King VL, Clark M, Brooner RK. A behavioral treatment for opioid-dependent patients with antisocial personality. <i>Journal of substance abuse treatment</i> . 2008;34(1):101-11. Available from: https://doi.org/10.1016/j.jsat.2007.02.009
Notzon DP, Mariani JJ, Pavlicova M, Glass A, Mahony AL, Brooks DJ, et al. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. <i>The American journal on addictions</i> . 2016;25(8):666-72. Available from: https://doi.org/10.1111/ajad.12467

Reference
Nunes EV, McGrath PJ, Quitkin FM, Ocepek-Welikson K, Stewart JW, Koenig T, et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug and alcohol dependence. 1995;39(3):185-95. Available from: https://doi.org/10.1016/0376-8716(95)01161-6
Nunes EV, McGrath PJ, Quitkin FM, Stewart JP, Harrison W, Tricamo E, et al. Imipramine treatment of alcoholism with comorbid depression. The American journal of psychiatry. 1993;150(6):963-5. Available from: https://doi.org/10.1176/ajp.150.6.963
Nuttbrock LA, Rahav M, Rivera JJ, Ng-Mak DS, Link BG. Outcomes of homeless mentally ill chemical abusers in community residences and a therapeutic community. Psychiatric services (Washington, DC). 1998;49(1):68-76. Available from: https://doi.org/10.1176/ps.49.1.68
Nuttbrock LH, Ng-Mak DS, Rahav M, Rivera JJ. Pre- and post-admission attrition of homeless, mentally ill chemical abusers referred to residential treatment programs. Addiction (Abingdon, England). 1997;92(10):1305-15.
O'Malley S S, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcoholism: Clinical & Experimental Research. 2007;31(4):625-34. Available from: https://doi.org/10.1111/j.1530-0277.2007.00347.x
Oslin DW. Treatment of late-life depression complicated by alcohol dependence. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2005;13(6):491-500. Available from: https://doi.org/10.1176/appi.ajgp.13.6.491
Petrakis I, Ralevski E, Nich C, Levinson C, Carroll K, Poling J, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. Journal of Clinical Psychopharmacology. 2007;27(2):160-5. Available from: https://doi.org/10.1016/j.biopsych.2006.03.074
Petrakis IL, Meshberg-Cohen S, Nich C, Kelly MM, Claudio T, Jane JS, et al. Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine. American Journal on Addictions. 2024;33(5):525-33. Available from: https://doi.org/10.1111/ajad.13557
Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Ralevski E, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biological Psychiatry. 2006;60(7):777-83. Available from: https://doi.org/10.1016/j.biopsych.2006.03.074

Reference
Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. <i>Neuropsychopharmacology</i> : official publication of the American College of Neuropsychopharmacology. 2012;37(4):996-1004. Available from: https://doi.org/10.1038/npp.2011.283
Powell BJ, Campbell JL, Landon JF, Liskow BI, Thomas HM, Nickel EJ, et al. A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. <i>Alcoholism, clinical and experimental research</i>. 1995;19(2):462-8. Available from: https://doi.org/10.1111/j.1530-0277.1995.tb01532.x
Raskind MA, Williams T, Holmes H, Hart K, Crews L, Poupore EL, et al. A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters. <i>Alcoholism: Clinical and Experimental Research</i>. 2023;47(2):348-60. Available from: https://doi.org/10.1111/acer.14989
Ries RK, Dyck DG, Short R, Srebnik D, Fisher A, Comtois KA. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. <i>Psychiatric services (Washington, DC)</i>. 2004;55(4):445-7. Available from: https://doi.org/10.1176/appi.ps.55.4.445
Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. <i>Biological Psychiatry</i>. 1998;44(7):633-7. Available from: https://doi.org/10.1016/s0006-3223(97)00509-x
Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. <i>Canadian journal of psychiatry Revue canadienne de psychiatrie</i>. 2006;51(8):531-9. Available from: https://doi.org/10.1177/070674370605100808
Rubio G, Martínez I, Recio A, Ponce G, López-Muñoz F, Alamo C, et al. Risperidone versus Zuclopenthixol in the Treatment of Schizophrenia with Substance Abuse Comorbidity: A Long-term Randomized, Controlled, Crossover Study. <i>The European Journal of Psychiatry</i>. 2006;20(3):133-46. Available from: https://doi.org/10.4321/S0213-61632006000300001
Sacks S, McKendrick K, Vazan P, Sacks JY, Cleland CM. Modified therapeutic community aftercare for clients triply diagnosed with HIV/AIDS and co-occurring mental and substance use disorders. <i>AIDS care</i>. 2011;23(12):1676-86. Available from: https://doi.org/10.1080/09540121.2011.582075
Salemink E, Rinck M, Becker E, Wiers RW, Lindenmeyer J. Does Comorbid Anxiety or Depression Moderate Effects of Approach Bias Modification in the Treatment of Alcohol Use Disorders? <i>Psychology of Addictive Behaviors</i>. 2022;36(5):547-54. Available from: https://doi.org/10.1037/adb0000642

Reference
Santa Ana EJ. Efficacy of group motivational interviewing (GMI) for psychiatric inpatients with chemical dependence. 2005;66:2839-. Available from: https://doi.org/10.1037/0022-006X.75.5.816
Saunders EC, McGovern MP, Lambert-Harris C, Meier A, McLeman B, Xie H. The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders. The American journal on addictions. 2015;24(8):722-31. Available from: https://doi.org/10.1111/ajad.12292
Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. The American journal on addictions. 2014;23(3):308-12. Available from: https://doi.org/10.1111/j.1521-0391.2014.12126.x
Smelson D, Kalman D, Losonczy M, Kline A, Sambamoorthi U, Hill L, et al. A Brief Treatment Engagement Intervention for Individuals with Co-occurring Mental Illness and Substance Use Disorders: Results of a Randomized Clinical Trial. Community mental health journal. 2012;48(2):127-32. Available from: https://doi.org/10.1007/s10597-010-9346-9
Smelson DA, Ziedonis D, Williams J, Losonczy MF, Williams J, Steinberg ML, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. Journal of Clinical Psychopharmacology. 2006;26(1):9-12. Available from: https://doi.org/10.1097/01.jcp.0000194624.07611.5e
Stein MD, Solomon DA, Anderson BJ, Herman DS, Anthony JL, Brown RA, et al. Persistence of antidepressant treatment effects in a pharmacotherapy plus psychotherapy trial for active injection drug users. The American journal on addictions. 2005;14(4):346-57. Available from: https://doi.org/10.1080/10550490591003684
Stein MD, Solomon DA, Herman DS, Anthony JL, Ramsey SE, Anderson BJ, et al. Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users. Archives of General Psychiatry. 2004;61(2):152-9. Available from: https://doi.org/10.1001/archpsyc.61.2.152
Swanson AJ, Pantalon MV, Cohen KR. Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. The Journal of nervous and mental disease. 1999;187(10):630-5. Available from: https://doi.org/10.1097/00005053-199910000-00007
Titievsky J, Seco G, Barranco M, Kyle EM. Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double-blind study. The Journal of clinical psychiatry. 1982;43(11):454-6.
Tollefson GD, Montague-Clouse J, Lancaster SP. Buspirone in comorbid alcohol dependency and generalized anxiety disorders. Drug Therapy. 1990;20:35-51.

Reference
Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). <i>Journal of Clinical Psychopharmacology</i> . 1992;12(1):19-26. Available from: https://doi.org/10.1097/00001573-199202000-00004
Toneatto T, Calderwood K. Cognitive-behavior therapy for concurrent anxiety and alcohol use disorder: A randomized control trial. <i>International Journal of Mental Health and Addiction</i> . 2015;13(2):297-306. Available from: https://doi.org/10.1007/s11469-014-9529-7
Tracy K, Babuscio T, Nich C, Kiluk B, Carroll KM, Petry NM, et al. Contingency Management to reduce substance use in individuals who are homeless with co-occurring psychiatric disorders. <i>The American journal of drug and alcohol abuse</i> . 2007;33(2):253-8. Available from: https://doi.org/10.1080/00952990601174931
Tripp JC, Haller M, Trim RS, Straus E, Bryan CJ, Davis BC, et al. Does exposure exacerbate symptoms in veterans with PTSD and alcohol use disorder? <i>Psychological trauma : theory, research, practice and policy</i> . 2021;13(8):920-8. Available from: https://doi.org/10.1037/tra0000634
Wang Z, Gao K, Kemp DE, Chan PK, Serrano MB, Conroy C, et al. Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. <i>Psychopharmacology bulletin</i> . 2010;43(4):5-21.
Wilson IC, Alltop LB, Riley L. Tofranil in the treatment of post alcoholic depressions. <i>Psychosomatics: Journal of Consultation and Liaison Psychiatry</i> . 1970;11(5):488-94. Available from: https://doi.org/10.1016/S0033-3182(70)71614-9
Wolitzky-Taylor K, Krull J, Rawson R, Roy-Byrne P, Ries R, Craske MG. Randomized clinical trial evaluating the preliminary effectiveness of an integrated anxiety disorder treatment in substance use disorder specialty clinics. <i>Journal of consulting and clinical psychology</i> . 2018;86(1):81-8. Available from: https://doi.org/10.1037/ccp0000276
Woody GE, O'Brien CP, Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. <i>Am J Psychiatry</i> . 1975;132(4):447-50. Available from: https://doi.org/10.1176/ajp.132.4.447
Wusthoff LE, Waal H, Grawe RW. The effectiveness of integrated treatment in patients with substance use disorders co-occurring with anxiety and/or depression—a group randomized trial. <i>BMC psychiatry</i> . 2014;14:67. Available from: https://doi.org/10.1186/1471-244X-14-67 .